Skip to main content
HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C
Home
Table of Contents
Test, Evaluate, Monitor
Treatment-Naive Patients
Treatment-Experienced Patients
Unique & Key Populations
About the Guidance
Home
Table of Contents
Introduction
Methods
Methods Table 1
Methods Table 2
Methods Table 3 Abbreviations
References
Test, Evaluate, Monitor
Testing and Linkage to Care
When and in Whom
Cost, Reimbursement, and Cost-Effectiveness
Monitoring
HCV Resistance
Treatment-Naive
Genotype 1
GT1a: No Cirrhosis
GT1a: Compensated
GT1b: No Cirrhosis
GT1b: Compensated
Genotype 2
GT2 : No Cirrhosis
GT2 : Compensated
Genotype 3
GT3 : No Cirrhosis
GT3 : Compensated
Genotype 4
GT4 : No Cirrhosis
GT4 : Compensated
Genotype 5 or 6
Treatment-Experienced
Genotype 1
GT1a : P/R : No Cirrhosis
GT1a : P/R : Compensated
GT1b : P/R : No Cirrhosis
GT1b : P/R : Compensated
GT1 : NS3 : No Cirrhosis
GT1 : NS3 : Compensated
GT1 : Non-NS5A : No Cirrhosis
GT1 : Non-NS5A : Compensated
GT1 : NS5A
Genotype 2
GT2 : P/R : No Cirrhosis
GT2 : P/R : Compensated
GT2 : DAA
Genotype 3
GT3 : P/R : No Cirrhosis
GT3 : P/R : Compensated
GT3 : DAA
Genotype 4
GT4 : P/R : No Cirrhosis
GT4 : P/R : Compensated
GT4 : DAA
Genotype 5 or 6
GT 5 or 6 : P/R
GT 5 or 6 : DAA
Unique & Key Populations
HIV/HCV Coinfection
Decompensated Cirrhosis
Post Liver Transplant
Renal Impairment
Kidney Transplant
Acute Infection
HCV in Pregnancy
HCV in Children
PWID, MSM & Corrections
People Who Inject Drugs
Men Who Have Sex With Men
Correctional Settings
About
Announcements
Organizations
Panel
Disclosures
Process
Citing and Permissions
Survey
Website Policies
Contact
You are here
Home
›
References
›
Owerkerk-Mahadevan 2016b
Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir.
Owerkerk-Mahadevan S, Sekar V, Peeters M, Peeters M
.
Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir.
Clin Pharmacokinet. 2016;55(2):197-208.
Publication Type:
Journal Article
Authors:
S Owerkerk-Mahadevan
;
Sekar, V.
;
Peeters, M.
;
et al
Source:
Clin Pharmacokinet, Volume 55, Issue 2, p.197-208 (2016)
Top